摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2-氨基-5-氯-4-甲基噻唑盐酸盐 | 5316-76-7

中文名称
2-氨基-5-氯-4-甲基噻唑盐酸盐
中文别名
——
英文名称
5-chloro-4-methylthiazol-2-amine
英文别名
2-amino-5-chloro-4-methyl-1,3-thiazole;5-chloro-4-methyl-thiazol-2-ylamine;5-Chlor-4-methyl-thiazol-2-ylamin;2-amino-5-chloro-4-methylthiazole;2-amino-5-chloro-2-methyl-thiazole;5-chloro-4-methyl-1,3-thiazol-2-amine
2-氨基-5-氯-4-甲基噻唑盐酸盐化学式
CAS
5316-76-7
化学式
C4H5ClN2S
mdl
MFCD10699130
分子量
148.616
InChiKey
WUTUCTHNAXSTGJ-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    104-108 °C
  • 沸点:
    273.0±20.0 °C(Predicted)
  • 密度:
    1.447±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    2
  • 重原子数:
    8
  • 可旋转键数:
    0
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.25
  • 拓扑面积:
    67.2
  • 氢给体数:
    1
  • 氢受体数:
    3

安全信息

  • 危险品标志:
    Xi
  • 海关编码:
    2934100090

SDS

SDS:3132dcfd725d7e3a792d1bd8523f19d0
查看
Material Safety Data Sheet

Section 1. Identification of the substance
Product Name: 2-Amino-5-chloro-4-methylthiazole
Synonyms:

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

Section 3. Composition/information on ingredients.
Ingredient name: 2-Amino-5-chloro-4-methylthiazole
CAS number: 5316-76-7

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C4H5ClN2S
Molecular weight: 148.6

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen chloride, sulfur oxides.

Section 11. Toxicological information
No data.

Section 12. Ecological information
No data.

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

Section 14. Transportation information
Non-harzardous for air and ground transportation.

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.


SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

  • 作为反应物:
    参考文献:
    名称:
    Oxazoles and their agricultural compositions
    摘要:
    具有化学式R--S(O).sub.n CH.sub.2 CH.sub.2 CH.dbd.CF.sub.2的化合物,其中R是苯基或从呋喃基,噻吩基,异噁唑基,异硫唑基,噁唑基,噻唑基,咪唑基,吡唑基,1,2,4-噁二唑基,1,2,4-硫二唑基,1,3,4-噁二唑基,1,3,4-硫二唑基,四唑基,吡啶基,吡啶嗪基,吡嗪基,1,2,3-三嗪基,1,3,4-三嗪基和1,3,5-三嗪基中选择的杂环基,所述苯基或杂环基可以选择地被可选择地取代的烷基,可选择地取代的烯烃基,炔基,环烷基,烷基环烷基,烷氧基,烯氧基,炔氧基,羟基烷基,烷氧基烷基,可选择地取代的芳基,可选择地取代的芳基烷基,可选择地取代的杂芳基,可选择地取代的杂芳基烷基,可选择地取代的芳氧基,可选择地取代的芳基氧基,可选择地取代的芳氧基烷基,可选择地取代的杂芳氧基,可选择地取代的杂芳基氧基烷基,卤代烷基,卤代烯烃基,卤代炔基,卤代烷氧基,卤代烯氧基,卤代炔氧基,卤素,羟基,氰基,硝基,--NR7R8,--NR7COR8,--NR7CSR8,--NR7SO2R8,--N(SO2R7)(SO2R8),--COR7,--CONR7R8,-烷基CONR7R8,--CR7NR8,--COOR7,--OCOR7,--SR7,--SOR7,--SO2R7,-烷基SR7,-烷基SOR7,-烷基SO2R7,--OSO2R7,--SO2NR7R8,--CSNR7R8,--SiR7R8R9,--OCH2CO2R7,--OCH2CH2CO2R7,--CONR7SO2R8,-烷基CONR7SO2R8,--NHCONR7R8,--NHCSNR7R8,或R1,R2,R3,R4,R5和R6的相邻对一起形成融合的5-或6-成员碳环或杂环环时;R7,R8和R9分别独立地是氢,可选择地取代的烷基,可选择地取代的烯烃基,炔基,可选择地取代的芳基或可选择地取代的芳基烷基,卤代烷基,卤代烯烃基,卤代炔基,卤素或羟基。
    公开号:
    US05705516A1
  • 作为产物:
    参考文献:
    名称:
    Thiazole derivatives, processes for production thereof and
    摘要:
    该公式化合物为:##STR1## 其中A为S、SO或SO2,R1为H或酰基,R2为H、烷基、羟基烷基、卤素或羧基,R3为吡啶基。这些化合物可用作治疗药剂,用于治疗风湿病、肾炎和血小板减少症等疾病。
    公开号:
    US05256675A1
点击查看最新优质反应信息

文献信息

  • [EN] MODIFIED PROTEINS AND PROTEIN DEGRADERS<br/>[FR] PROTÉINES MODIFIÉES ET AGENTS DE DÉGRADATION DE PROTÉINES
    申请人:CULLGEN SHANGHAI INC
    公开号:WO2021239117A1
    公开(公告)日:2021-12-02
    Provided herein are compounds, pharmaceutical compositions, and methods for binding or degrading target proteins. Further provided herein are compounds having a DNA damage-binding protein 1 (DDB1) binding moiety. Some such embodiments include a linker. Some such embodiments include a target protein binding moiety. Further provided herein are ligand-DDB1 complexes. Further provided herein are in vivo modified DDB1 proteins.
    本文提供了结合或降解靶蛋白的化合物、药物组合物和方法。本文还提供了具有DNA损伤结合蛋白1(DDB1)结合基团的化合物。其中一些实施例包括连接物。其中一些实施例包括靶蛋白结合基团。本文还提供了配体-DDB1复合物。本文还提供了体内修饰的DDB1蛋白。
  • [EN] NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS AND USES THEREOF<br/>[FR] NOUVEAUX COMPOSÉS EN TANT QUE LIGANDS DE RÉCEPTEUR DE CANNABINOÏDE ET LEURS UTILISATIONS
    申请人:ABBOTT LAB
    公开号:WO2009067613A1
    公开(公告)日:2009-05-28
    The present invention relates to compounds of formula (I), or pharmaceutical salts, prodrugs, salts of prodrugs, or combinations thereof, formula (I). wherein R1, R2, R3, R4, and L1 are defined in the specfication, compositions comprising such compounds, and methods of treating conditions and disorders using such compounds and compositions. The present invention also relates to compounds of formula (II), or pharmaceutical salts, prodrugs, salts of prodrugs, or combinations thereof, formula (II). wherein R1a, R2a, Rx, and n are as defined in the specification, compositions comprising such compounds, and methods of treating conditions and disorders using such compounds and compositions.
    本发明涉及式(I)的化合物,或药用盐、前药、前药的盐或其组合物,式(I)。其中R1、R2、R3、R4和L1在规范中定义,包括含有这种化合物的组合物,以及使用这种化合物和组合物治疗疾病和疾病的方法。本发明还涉及式(II)的化合物,或药用盐、前药、前药的盐或其组合物,式(II)。其中R1a、R2a、Rx和n如规范中定义,包括含有这种化合物的组合物,以及使用这种化合物和组合物治疗疾病和疾病的方法。
  • THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF
    申请人:GENENTECH, INC.
    公开号:US20180105504A1
    公开(公告)日:2018-04-19
    The invention provides a compound of formula I: or a pharmaceutically acceptable salt thereof, wherein the variables X, Y 1 -Y 5 , R 1 , R 2 , R 3 , R 4 , and Het have the meaning as described herein, and compositions containing such compounds and methods for using such compounds and compositions.
    本发明提供了一种式I化合物:或其药学上可接受的盐,其中变量X、Y1-Y5、R1、R2、R3、R4和Het的含义如本文所述,以及含有此类化合物的组合物和使用此类化合物及组合物的方法。
  • Studies in Chemotherapy. XIII. Antimalarials. Halogenated Sulfanilamidoheterocycles
    作者:J. P. English、J. H. Clark、J. W. Clapp、Doris Seeger、R. H. Ebel
    DOI:10.1021/ja01207a033
    日期:1946.3
  • Garreau, Bulletin de la Societe Chimique de France, 1954, p. 1048,1052
    作者:Garreau
    DOI:——
    日期:——
查看更多

同类化合物

伊莫拉明 (5aS,6R,9S,9aR)-5a,6,7,8,9,9a-六氢-6,11,11-三甲基-2-(2,3,4,5,6-五氟苯基)-6,9-甲基-4H-[1,2,4]三唑[3,4-c][1,4]苯并恶嗪四氟硼酸酯 (5-氨基-1,3,4-噻二唑-2-基)甲醇 齐墩果-2,12-二烯[2,3-d]异恶唑-28-酸 黄曲霉毒素H1 高效液相卡套柱 非昔硝唑 非布索坦杂质Z19 非布索坦杂质T 非布索坦杂质K 非布索坦杂质E 非布索坦杂质67 非布索坦杂质65 非布索坦杂质64 非布索坦杂质61 非布索坦代谢物67M-4 非布索坦代谢物67M-2 非布索坦代谢物 67M-1 非布索坦-D9 非布索坦 非唑拉明 雷西纳德杂质H 雷西纳德 阿西司特 阿莫奈韦 阿米苯唑 阿米特罗13C2,15N2 阿瑞匹坦杂质 阿格列扎 阿扎司特 阿尔吡登 阿塔鲁伦中间体 阿培利司N-1 阿哌沙班杂质26 阿哌沙班杂质15 阿可替尼 阿作莫兰 阿佐塞米 镁(2+)(Z)-4'-羟基-3'-甲氧基肉桂酸酯 锌1,2-二甲基咪唑二氯化物 铵2-(4-氯苯基)苯并恶唑-5-丙酸盐 铬酸钠[-氯-3-[(5-二氢-3-甲基-5-氧代-1-苯基-1H-吡唑-4-基)偶氮]-2-羟基苯磺酸基][4-[(3,5-二氯-2-羟基苯 铁(2+)乙二酸酯-3-甲氧基苯胺(1:1:2) 钠5-苯基-4,5-二氢吡唑-1-羧酸酯 钠3-[2-(2-壬基-4,5-二氢-1H-咪唑-1-基)乙氧基]丙酸酯 钠3-(2H-苯并三唑-2-基)-5-仲-丁基-4-羟基苯磺酸酯 钠(2R,4aR,6R,7R,7aS)-6-(2-溴-9-氧代-6-苯基-4,9-二氢-3H-咪唑并[1,2-a]嘌呤-3-基)-7-羟基四氢-4H-呋喃并[3,2-D][1,3,2]二氧杂环己膦烷e-2-硫醇2-氧化物 野麦枯 野燕枯 醋甲唑胺